Park Hotels & Resorts Inc. (PK)
NYSE: PK · Real-Time Price · USD
10.24
-0.42 (-3.94%)
At close: Aug 1, 2025, 4:00 PM
10.40
+0.16 (1.56%)
After-hours: Aug 1, 2025, 7:48 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Hold" and an average price target of $12.85, which forecasts a 25.49% increase in the stock price over the next year. The lowest target is $10 and the highest is $20.
Price Target: $12.85 (+25.49%)
Analyst Consensus: Hold
* Price targets were last updated on Jul 1, 2025.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 2 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 0 | 0 | 0 |
| Hold | 5 | 5 | 7 | 8 | 8 | 9 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $10 → $11 | Hold | Maintains | $10 → $11 | +7.42% | Jul 1, 2025 |
| JP Morgan | JP Morgan | Sell Initiates $10 | Sell | Initiates | $10 | -2.34% | Jun 23, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $16 → $11 | Strong Buy → Hold | Downgrades | $16 → $11 | +7.42% | May 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $13 | Buy → Hold | Downgrades | $13 | +26.95% | May 16, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $16 → $13 | Buy | Maintains | $16 → $13 | +26.95% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
2.67B
from 2.61B
Increased by 2.07%
Revenue Next Year
2.73B
from 2.67B
Increased by 2.55%
EPS This Year
0.09
from 1.01
Decreased by -91.17%
EPS Next Year
0.63
from 0.09
Increased by 603.39%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.8B | 2.9B | 3.1B | ||
| Avg | 2.7B | 2.7B | 2.8B | ||
| Low | 2.5B | 2.5B | 2.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.5% | 10.1% | 11.7% | ||
| Avg | 2.1% | 2.6% | 3.1% | ||
| Low | -5.6% | -5.4% | -4.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.26 | 0.96 | 1.13 | ||
| Avg | 0.09 | 0.63 | 0.94 | ||
| Low | -0.09 | 0.02 | 0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -74.0% | 971.2% | 80.7% | ||
| Avg | -91.2% | 603.4% | 50.2% | ||
| Low | - | -78.0% | 17.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.